

Special Issue

Emerging Biomarkers Used in Radiochemotherapy

Message from the Guest Editors

Dear colleagues, Unlike great advances made in targeted chemotherapy by profiling tumors for addressable mutations, no such treatment individualization has been achieved yet for radiotherapy or combined radiochemotherapy. Given the broad spectra of both treatment outcomes and side-effects, a substantial impact of tumors and host biomarkers is presumed. With the rapid progress in the technical exploration of molecular features in the (epi-)genome, transcriptome, proteome, and metabolome there is an emerging potential for the discovery of promising biomarkers in radiochemotherapy. This Special Issue invites experts in this field to present and discuss data on prognostic and predictive biomarkers assessed in retrospective and prospective clinical cohorts with various kinds of radiotherapy or radiochemotherapy applied. Sophisticated data on functional mechanisms of biomarkers are also welcome.

Guest Editors

Dr. Markus Schirmer

Department of Radiotherapy and Radiation Oncology, University Medicine Goettingen (UMG), Robert-Koch-Str. 40, 37075 Goettingen, Germany

Prof. Dr. Stefan Rieken

Department of Radiotherapy and Radiation Oncology, University Medicine Goettingen (UMG), Robert-Koch-Str. 40, 37075 Goettingen, Germany

Deadline for manuscript submissions

closed (31 March 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/72210

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)